VRCA

Verrica

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 0

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About VRCA

Verrica Pharmaceuticals Inc.

A dermatology therapeutics company developing medications for skin diseases requiring medical interventions

Industry

Pharmaceutical

Established Date

07/03/2013

Listing Date

06/15/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.verrica.com

Security Type

Common stock

Office address

44 West Gay Street, Suite 400, West Chester, PA 19380

Business

Introduction

Verrica Pharmaceuticals Inc., was incorporated under the laws of the State of Delaware on July 3, 2013. The company is a clinical-stage medical dermatology company dedicated to identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases and meeting significant needs. The company's lead product candidate, VP-102, is a patented drug device combination whose novel plaque hormone topical solution is a widely recognized natural source drug for the treatment of local skin diseases, administered through its single-use precision applicator. The company is initially developing VP-102 for the treatment of molluscum contagiosum or molluscum, a highly contagious, mostly pediatric viral skin disease and common wart. There are currently no products approved by the U.S. Food and Drug Administration or the FDA, and there is no established standard of care for these diseases, resulting in two significant untreated populations with the largest unmet needs in dermatology. In addition to the patent protection they are seeking, VP-102 also has the potential to be the first FDA-approved new product for mollusks and their active pharmaceutical ingredients or APIs, namely New Chemical Entities or NCEs, with many years of generic regulatory exclusivity associated with this designation.

Company Financials

EPS

VRCA has released its 2024 Q4 earnings. EPS was reported at -0.24, versus the expected -0.24, meeting expectations. The chart below visualizes how VRCA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

VRCA has released its 2024 Q4 earnings report, with revenue of 344.00K, reflecting a YoY change of -82.70%, and net profit of -16.20M, showing a YoY change of 34.18%. The Sankey diagram below clearly presents VRCA’s revenue sources and cost distribution.